GLP-1 Receptor Agonist Market Research, Analysis and Forecast to 2032
The GLP-1 receptor agonist market size is estimated to cross US$ 11.24 Billion by 2032, with a CAGR of 10.84%. According to the World Diabetes Federation, almost 463 million people aged 20 to 70 worldwide are anticipated to have diabetes in 2019. Furthermore, according to the WHO, over 1.9 million persons were deemed to be overweight in 2016. Obesity and overweight people are more likely to suffer cardiovascular and gastrointestinal diseases, as well as diabetes. The market for GLP-1 receptor agonists is being driven by an increase in the number of patients classified as obese or diabetes. An increase in these figures is likely to drive the uptake of GLP-1 receptor agonists over the predicted period. In 2019, North America accounted for more than 70% of the market. This could be related to the increased use of GLP-1 Receptor Agonists, as well as a well-established demand-supply chain that includes the pharmaceutical and biopharmaceutical industries. Europe is the second-largest market...